[
  {
    "ts": null,
    "headline": "Biogen Inc. stock outperforms competitors on strong trading day",
    "summary": "Biogen Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=3ac95b866d62e2eb43782abd2c2c5bf9a4bd350d6d1641d06e4a432beb45873f",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753981680,
      "headline": "Biogen Inc. stock outperforms competitors on strong trading day",
      "id": 136229893,
      "image": "",
      "related": "BIIB",
      "source": "MarketWatch",
      "summary": "Biogen Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=3ac95b866d62e2eb43782abd2c2c5bf9a4bd350d6d1641d06e4a432beb45873f"
    }
  },
  {
    "ts": null,
    "headline": "Biogen Lifts Outlook As Rare Disease And Alzheimer's Drug Sales Accelerate",
    "summary": "Biogen Inc. (NASDAQ:BIIB) reported on Thursday that the second quarter of 2025 adjusted earnings per share were $5.47, up 4% year over year, beating the analyst consensus of $4.06. The company reported sales of $2.65 billion, up 7% year over year on a reported basis, 8% on constant currency, beating the consensus of $2.32 billion. Multiple sclerosis revenue of $1.1 billion decreased by 4% (down 4% on constant currency). Sales of the multiple sclerosis drug Tysabri were down to $454.6 million fro",
    "url": "https://finnhub.io/api/news?id=eb61b4a4732c6fd2d642d2884db3f704a58df676a7d65f2d12a6d29ca88a053e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753976998,
      "headline": "Biogen Lifts Outlook As Rare Disease And Alzheimer's Drug Sales Accelerate",
      "id": 136155600,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Biogen Inc. (NASDAQ:BIIB) reported on Thursday that the second quarter of 2025 adjusted earnings per share were $5.47, up 4% year over year, beating the analyst consensus of $4.06. The company reported sales of $2.65 billion, up 7% year over year on a reported basis, 8% on constant currency, beating the consensus of $2.32 billion. Multiple sclerosis revenue of $1.1 billion decreased by 4% (down 4% on constant currency). Sales of the multiple sclerosis drug Tysabri were down to $454.6 million fro",
      "url": "https://finnhub.io/api/news?id=eb61b4a4732c6fd2d642d2884db3f704a58df676a7d65f2d12a6d29ca88a053e"
    }
  },
  {
    "ts": null,
    "headline": "Biogen's Q2 Earnings & Sales Beat, 2025 Outlook Raised, Stock Up",
    "summary": "BIIB posts Q2 earnings and sales beat, lifts 2025 outlook on new drug growth and displays resilient MS performance.",
    "url": "https://finnhub.io/api/news?id=a7bfda5b6979f20daad35b336b5ef8b78eec49065a494f0181eefef911334bc0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753973280,
      "headline": "Biogen's Q2 Earnings & Sales Beat, 2025 Outlook Raised, Stock Up",
      "id": 136155601,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "BIIB posts Q2 earnings and sales beat, lifts 2025 outlook on new drug growth and displays resilient MS performance.",
      "url": "https://finnhub.io/api/news?id=a7bfda5b6979f20daad35b336b5ef8b78eec49065a494f0181eefef911334bc0"
    }
  },
  {
    "ts": null,
    "headline": "Biogen Inc. (BIIB) Q2 2025 Earnings Call Transcript",
    "summary": "Biogen Inc. (NASDAQ:BIIB) Q2 2025 Earnings Conference Call July 31, 2025 8:30 AM ETCompany ParticipantsAlisha A.",
    "url": "https://finnhub.io/api/news?id=deaf8798f892727f0cec9d8041a6661e28cc2dfb096de433785d1a58134e2df4",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753971870,
      "headline": "Biogen Inc. (BIIB) Q2 2025 Earnings Call Transcript",
      "id": 136156681,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "BIIB",
      "source": "SeekingAlpha",
      "summary": "Biogen Inc. (NASDAQ:BIIB) Q2 2025 Earnings Conference Call July 31, 2025 8:30 AM ETCompany ParticipantsAlisha A.",
      "url": "https://finnhub.io/api/news?id=deaf8798f892727f0cec9d8041a6661e28cc2dfb096de433785d1a58134e2df4"
    }
  },
  {
    "ts": null,
    "headline": "Biogen (BIIB) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates",
    "summary": "Although the revenue and EPS for Biogen (BIIB) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.",
    "url": "https://finnhub.io/api/news?id=655744cf38e515c8955b7f1d7162e657e55d1e382984b71279a93c698c9353fb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753968609,
      "headline": "Biogen (BIIB) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates",
      "id": 136155602,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Although the revenue and EPS for Biogen (BIIB) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.",
      "url": "https://finnhub.io/api/news?id=655744cf38e515c8955b7f1d7162e657e55d1e382984b71279a93c698c9353fb"
    }
  },
  {
    "ts": null,
    "headline": "Ionis Beats on Q2 Earnings & Sales, Stock Up 5% on Raised '25 Outlook",
    "summary": "Ionis crushes Q2 estimates with EPS of $0.86 and sales of $452 million, lifting its 2025 revenue forecast and sending shares up 5%.",
    "url": "https://finnhub.io/api/news?id=e732b152c6b10b4fca608183e877a8ad9b44b6899a22f56601054a16c2035684",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753967400,
      "headline": "Ionis Beats on Q2 Earnings & Sales, Stock Up 5% on Raised '25 Outlook",
      "id": 136154347,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Ionis crushes Q2 estimates with EPS of $0.86 and sales of $452 million, lifting its 2025 revenue forecast and sending shares up 5%.",
      "url": "https://finnhub.io/api/news?id=e732b152c6b10b4fca608183e877a8ad9b44b6899a22f56601054a16c2035684"
    }
  },
  {
    "ts": null,
    "headline": "Biogen Inc. 2025 Q2 - Results - Earnings Call Presentation",
    "summary": "Biogen Inc. 2025 Q2 - Results - Earnings Call Presentation",
    "url": "https://finnhub.io/api/news?id=05b5a71e55451490848d9aa36c213672fea9bbed6dc0f871127939ee3814afc3",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753961426,
      "headline": "Biogen Inc. 2025 Q2 - Results - Earnings Call Presentation",
      "id": 136154750,
      "image": "",
      "related": "BIIB",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=05b5a71e55451490848d9aa36c213672fea9bbed6dc0f871127939ee3814afc3"
    }
  },
  {
    "ts": null,
    "headline": "Biogen (NASDAQ:BIIB) Reports Bullish Q2",
    "summary": "Biotech company Biogen (NASDAQ:BIIB) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 7.3% year on year to $2.65 billion. Its non-GAAP profit of $5.47 per share was 41.3% above analysts’ consensus estimates.",
    "url": "https://finnhub.io/api/news?id=fe71c921775fd63ea133f96a126f6c8b99317eb4128d39ba458034a408f3ae03",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753961094,
      "headline": "Biogen (NASDAQ:BIIB) Reports Bullish Q2",
      "id": 136152200,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Biotech company Biogen (NASDAQ:BIIB) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 7.3% year on year to $2.65 billion. Its non-GAAP profit of $5.47 per share was 41.3% above analysts’ consensus estimates.",
      "url": "https://finnhub.io/api/news?id=fe71c921775fd63ea133f96a126f6c8b99317eb4128d39ba458034a408f3ae03"
    }
  },
  {
    "ts": null,
    "headline": "Biogen Inc. (BIIB) Surpasses Q2 Earnings and Revenue Estimates",
    "summary": "Biogen (BIIB) delivered earnings and revenue surprises of +39.19% and +13.89%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?",
    "url": "https://finnhub.io/api/news?id=cab8c2b2225dd066a2724ffab3547f39f22d10971e9c172f6c823cf565185903",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753960801,
      "headline": "Biogen Inc. (BIIB) Surpasses Q2 Earnings and Revenue Estimates",
      "id": 136152201,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Biogen (BIIB) delivered earnings and revenue surprises of +39.19% and +13.89%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?",
      "url": "https://finnhub.io/api/news?id=cab8c2b2225dd066a2724ffab3547f39f22d10971e9c172f6c823cf565185903"
    }
  },
  {
    "ts": null,
    "headline": "Biogen lifts full-year outlook amid Alzheimer’s drug strength, sending shares up",
    "summary": "Investing.com - Shares of Biogen (NASDAQ:BIIB) rose in premarket U.S. trading on Thursday after the drugmaker posted better-than-anticipated first-quarter revenue and raised its full-year guidance thanks in part to solid sales of its Alzheimer’s drug.",
    "url": "https://finnhub.io/api/news?id=f18520da70879589b802b7b5b1c42c6c48b98fa3a55d78a5a145c60a9a3ecb5b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753958974,
      "headline": "Biogen lifts full-year outlook amid Alzheimer’s drug strength, sending shares up",
      "id": 136151739,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Investing.com - Shares of Biogen (NASDAQ:BIIB) rose in premarket U.S. trading on Thursday after the drugmaker posted better-than-anticipated first-quarter revenue and raised its full-year guidance thanks in part to solid sales of its Alzheimer’s drug.",
      "url": "https://finnhub.io/api/news?id=f18520da70879589b802b7b5b1c42c6c48b98fa3a55d78a5a145c60a9a3ecb5b"
    }
  },
  {
    "ts": null,
    "headline": "Sales of Leqembi® totaled 23.1 billion yen in the second quarter 2025",
    "summary": "BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today published the preliminary global revenue for Leqembi during the second quarter 2025, in conjunction with their partner Biogen's second quarter report. In total, sales of JPY 23.1 billion were recorded in the period. This results in a royalty to BioArctic amounting to SEK 162.5 million which is an increase of approximately 280 percent compared to the royalty obtained by BioArctic in Q2 2024.",
    "url": "https://finnhub.io/api/news?id=7b75af14bdd466bdb24c0ca7b0b8fa2674a87e179f91673b3c2c0636537e71de",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753957380,
      "headline": "Sales of Leqembi® totaled 23.1 billion yen in the second quarter 2025",
      "id": 136152203,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today published the preliminary global revenue for Leqembi during the second quarter 2025, in conjunction with their partner Biogen's second quarter report. In total, sales of JPY 23.1 billion were recorded in the period. This results in a royalty to BioArctic amounting to SEK 162.5 million which is an increase of approximately 280 percent compared to the royalty obtained by BioArctic in Q2 2024.",
      "url": "https://finnhub.io/api/news?id=7b75af14bdd466bdb24c0ca7b0b8fa2674a87e179f91673b3c2c0636537e71de"
    }
  },
  {
    "ts": null,
    "headline": "Biogen raises annual profit forecast on strong demand for rare disease drugs",
    "summary": "Its shares rose 5.4% in premarket trading, with the company also topping sales estimates for its keenly-watched Alzheimer's treatment Leqembi, which has struggled with slower uptake.  Meanwhile, Biogen said it does not expect President Donald Trump's tariffs to have a material impact on its profits as a significant portion of its U.S. revenue comes through domestic manufacturing.",
    "url": "https://finnhub.io/api/news?id=efee561e2b12f55c5ea0003229f3ded7909dc72f26be827225e719dc70e2e494",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753957044,
      "headline": "Biogen raises annual profit forecast on strong demand for rare disease drugs",
      "id": 136152204,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Its shares rose 5.4% in premarket trading, with the company also topping sales estimates for its keenly-watched Alzheimer's treatment Leqembi, which has struggled with slower uptake.  Meanwhile, Biogen said it does not expect President Donald Trump's tariffs to have a material impact on its profits as a significant portion of its U.S. revenue comes through domestic manufacturing.",
      "url": "https://finnhub.io/api/news?id=efee561e2b12f55c5ea0003229f3ded7909dc72f26be827225e719dc70e2e494"
    }
  },
  {
    "ts": null,
    "headline": "Multiple Sclerosis Clinical Trials Market Landscape Report 2025 Featuring Biogen, Novartis, Sanofi, Merck, Teva, Bayer, Roche, Bristol-Myers Squibb, Laboratory Corp of America, IQVIA",
    "summary": "Discover key insights with the \"Multiple Sclerosis - Global Clinical Trials Review, 2025\" report. Gain an overview of global MS clinical trial landscapes, including data by region, phase, and sponsor. Identify top drugs and trial trends to optimize strategies. Enhance decision-making and competitive edge.Dublin, July 31, 2025 (GLOBE NEWSWIRE) -- The \"Multiple Sclerosis - Global Clinical Trials Review, 2025\" clinical trials has been added to ResearchAndMarkets.com's offering.The clinical trial re",
    "url": "https://finnhub.io/api/news?id=f304a180423e033b5a2b7661e14cdb110733c435dcaf9533a22205491e1b0c7e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753954980,
      "headline": "Multiple Sclerosis Clinical Trials Market Landscape Report 2025 Featuring Biogen, Novartis, Sanofi, Merck, Teva, Bayer, Roche, Bristol-Myers Squibb, Laboratory Corp of America, IQVIA",
      "id": 136151856,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Discover key insights with the \"Multiple Sclerosis - Global Clinical Trials Review, 2025\" report. Gain an overview of global MS clinical trial landscapes, including data by region, phase, and sponsor. Identify top drugs and trial trends to optimize strategies. Enhance decision-making and competitive edge.Dublin, July 31, 2025 (GLOBE NEWSWIRE) -- The \"Multiple Sclerosis - Global Clinical Trials Review, 2025\" clinical trials has been added to ResearchAndMarkets.com's offering.The clinical trial re",
      "url": "https://finnhub.io/api/news?id=f304a180423e033b5a2b7661e14cdb110733c435dcaf9533a22205491e1b0c7e"
    }
  },
  {
    "ts": null,
    "headline": "Biogen Raises 2025 Outlook After Momentum in 1H",
    "summary": "Biogen Raises 2025 Outlook After Momentum in 1H",
    "url": "https://finnhub.io/api/news?id=abcf80af83ca755a07b5846c255af1d8bdf93f5382842bb846c2c57dd4834969",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753944660,
      "headline": "Biogen Raises 2025 Outlook After Momentum in 1H",
      "id": 136229894,
      "image": "",
      "related": "BIIB",
      "source": "MarketWatch",
      "summary": "Biogen Raises 2025 Outlook After Momentum in 1H",
      "url": "https://finnhub.io/api/news?id=abcf80af83ca755a07b5846c255af1d8bdf93f5382842bb846c2c57dd4834969"
    }
  }
]